Summary

Adding taxanes to an anthracycline-based chemotherapy regimen in the adjuvant setting has become a standard approach in the management of patients with breast cancer. However, long-term outcomes data are still lacking regarding the safety and efficacy of this approach. This article presents data from the 10-year final safety and efficacy analyses of the Intergroup Phase 3 BIG 2-98 trial [NCT00174655].